[go: up one dir, main page]

WO2004059293A3 - Markers for differential diagnosis and methods of use thereof - Google Patents

Markers for differential diagnosis and methods of use thereof Download PDF

Info

Publication number
WO2004059293A3
WO2004059293A3 PCT/US2003/041453 US0341453W WO2004059293A3 WO 2004059293 A3 WO2004059293 A3 WO 2004059293A3 US 0341453 W US0341453 W US 0341453W WO 2004059293 A3 WO2004059293 A3 WO 2004059293A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
differential diagnosis
markers
diseases
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/041453
Other languages
French (fr)
Other versions
WO2004059293A2 (en
Inventor
Kenneth F Buechler
Alan Maisel
Joseph Michael Anderberg
Paul H Mcpherson
Jeffrey R Dahlen
Howard J Kirchick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere San Diego Inc
Original Assignee
Biosite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/330,696 external-priority patent/US7713705B2/en
Priority claimed from US10/371,149 external-priority patent/US20030199000A1/en
Priority claimed from US10/603,891 external-priority patent/US20040253637A1/en
Priority claimed from US10/673,077 external-priority patent/US20040209307A1/en
Priority claimed from US10/714,078 external-priority patent/US20040219509A1/en
Priority to EP03810896A priority Critical patent/EP1587955A4/en
Priority to AU2003302340A priority patent/AU2003302340B8/en
Application filed by Biosite Inc filed Critical Biosite Inc
Priority to CA002511501A priority patent/CA2511501A1/en
Priority to JP2005510072A priority patent/JP2006526140A/en
Publication of WO2004059293A2 publication Critical patent/WO2004059293A2/en
Publication of WO2004059293A3 publication Critical patent/WO2004059293A3/en
Priority to IL169348A priority patent/IL169348A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9123—Phosphotransferases in general with a nitrogenous group as acceptor (2.7.3), e.g. histidine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides methods for the identification and use of diagnostic markers for differential diagnosis of diseases and/or conditions. In a various aspects, the invention relates to methods and compositions able to determine the presence or absence of one, and preferably a plurality, of diseases or conditions that exhibit one or more similar or identical symptoms. Such methods and compositions can be used to provide assays and assay devices for use in determining the disease or condition underlying one or more non-specific symptoms exhibited in a clinical setting.
PCT/US2003/041453 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof Ceased WO2004059293A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2005510072A JP2006526140A (en) 2002-12-24 2003-12-23 Marker for differential diagnosis and method of using the same
CA002511501A CA2511501A1 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof
EP03810896A EP1587955A4 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof
AU2003302340A AU2003302340B8 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof
IL169348A IL169348A0 (en) 2002-12-24 2005-06-23 Markers for differential diagnosis and methods of use thereof

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US43630102P 2002-12-24 2002-12-24
US60/436,301 2002-12-24
US10/330,696 US7713705B2 (en) 2002-12-24 2002-12-27 Markers for differential diagnosis and methods of use thereof
US10/330,696 2002-12-27
US10/371,149 2003-02-20
US10/371,149 US20030199000A1 (en) 2001-08-20 2003-02-20 Diagnostic markers of stroke and cerebral injury and methods of use thereof
US10/603,891 2003-06-24
US10/603,891 US20040253637A1 (en) 2001-04-13 2003-06-24 Markers for differential diagnosis and methods of use thereof
US10/673,077 US20040209307A1 (en) 2001-08-20 2003-09-26 Diagnostic markers of stroke and cerebral injury and methods of use thereof
US10/673,077 2003-09-26
US10/714,078 2003-11-14
US10/714,078 US20040219509A1 (en) 2001-08-20 2003-11-14 Diagnostic markers of stroke and cerebral injury and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2004059293A2 WO2004059293A2 (en) 2004-07-15
WO2004059293A3 true WO2004059293A3 (en) 2005-03-31

Family

ID=32686403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041453 Ceased WO2004059293A2 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof

Country Status (5)

Country Link
EP (1) EP1587955A4 (en)
JP (1) JP2006526140A (en)
AU (1) AU2003302340B8 (en)
CA (1) CA2511501A1 (en)
WO (1) WO2004059293A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US7842472B2 (en) 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US8029982B2 (en) 2004-01-20 2011-10-04 Alere San Diego, Inc. Biomarkers for sepsis
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
US8524462B2 (en) 2006-11-14 2013-09-03 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
US9395355B2 (en) 2007-12-28 2016-07-19 Roche Diagnostics Operations, Inc. Assessment of physiological conditions
US9494598B2 (en) 2006-04-04 2016-11-15 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US9541550B2 (en) 2011-05-09 2017-01-10 Sekisui Medical Co., Ltd. Method for immunologically measuring soluble LR11
US10732188B2 (en) 2011-12-01 2020-08-04 Roche Diagnostics Operations, Inc. NT-proANP and NT-proBNP for the diagnosis of stroke

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
MXPA03004105A (en) 2002-05-14 2004-10-15 Hoffmann La Roche Making a prognosis in cases of cardiac disease using a combination of markers.
CN1742087A (en) 2002-11-12 2006-03-01 贝克顿迪金森公司 Diagnosis of sepsis or SIRS using biomarker
WO2004044555A2 (en) 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
EP1519194A1 (en) * 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
DK1747015T3 (en) * 2004-04-26 2012-10-22 Janssen Biotech Inc Process for solution phase biopanoring using engineered lure proteins
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
ES2359822T3 (en) 2004-07-23 2011-05-27 Aspenbio Pharma, Inc. PROCEDURE AND DEVICES FOR THE APPENDICITIS DIAGNOSIS.
DE102004041659A1 (en) * 2004-08-27 2006-03-02 Institut Virion/Serion Gmbh Test device for the in vitro diagnosis of multi-analyte tests and their use
ITFI20040243A1 (en) * 2004-11-25 2005-02-25 Paola Romagnani DIAGNOSTIC METHOD FOR REJECTION OF TRANSPLANTED ORGAN
JP4828550B2 (en) * 2005-02-17 2011-11-30 エフ．ホフマン−ラ ロシュ アーゲー Use of the NT-proANP / NT-proBNP ratio to diagnose cardiac dysfunction
EP1869463A4 (en) 2005-04-15 2010-05-05 Becton Dickinson Co Diagnosis of sepsis
JP2008544224A (en) * 2005-06-09 2008-12-04 バイオサイト インコーポレイテッド Methods and compositions for diagnosis of venous thromboembolism
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
EP1904846A4 (en) * 2005-06-29 2009-03-18 Rules Based Medicine Inc Methods and kits for the diagnosis of acute coronary syndrome
EP1915613A4 (en) * 2005-07-08 2008-11-05 Philadelphia Health & Educatio METHODS FOR CONTROLLING NEUROINFLAMMATION DESTRUCTION OF NEURONS AND TREATING DISEASES HAVING A PHOSPHOLIPASE A2-RELATED INFLAMMATORY COMPONENT
EP1915465A2 (en) * 2005-07-14 2008-04-30 Inverness Medical Switzerland GmbH Mitochondrial markers of ischemia
DE102005034174A1 (en) * 2005-07-21 2007-02-08 B.R.A.H.M.S Ag CSF in vitro diagnostic procedure for dementia and neuroinflammatory diseases
DE102005036094A1 (en) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro method for the diagnosis of neurodegenerative diseases
JP2007082433A (en) * 2005-09-20 2007-04-05 Niigata Univ Malignant brain tumor marker gene and use thereof
US20080227713A1 (en) * 2005-10-03 2008-09-18 Protter Andrew A Oxidized Human Bnp
CA2633291A1 (en) * 2005-12-15 2007-07-12 Becton Dickinson And Company Diagnosis of sepsis
EP1845379A1 (en) * 2006-04-13 2007-10-17 F. Hoffmann-La Roche AG Means and methods for the differentiation of cardiac and pulmonary causes of shortness of breath
US8790871B2 (en) 2006-05-09 2014-07-29 Musc Foundation For Research Development Detecting diastolic heart failure by protease and protease inhibitor plasma profiling
DE102006023175A1 (en) 2006-05-17 2007-11-22 B.R.A.H.M.S Aktiengesellschaft In vitro diagnostic and early diagnosis of neurodegenerative diseases
DE102006027818A1 (en) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative diseases
DE102006034142A1 (en) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Method for controlling the therapy of heart failure patients by the in vitro determination of threshold levels of vasoactive peptides
EP1882947A1 (en) * 2006-07-28 2008-01-30 F. Hoffmann-La Roche AG Means and methods for the differentation of cardiac and pulmonary causes of acute shortness of breath
BRPI0715126B8 (en) * 2006-08-04 2021-07-27 Medizinische Hochschule Hannover methods for risk assessment of cardiac interventions and gdf-15-based uses
CA2660286A1 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP1909206A1 (en) * 2006-09-11 2008-04-09 Roche Diagnostics GmbH Improvement of measuring range of a chromatographic rapid test
EP1901072B1 (en) * 2006-09-15 2009-11-25 F. Hoffman-la Roche AG Biochemical markers for acute pulmonary embolism
US8449864B2 (en) 2006-10-20 2013-05-28 The Board Of Trustees Of The Leland Stanford Junior University Neurotensin as a marker and therapeutic target for sepsis
DE102006053442A1 (en) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnosis and risk stratification of infections and chronic diseases of the respiratory and lungs by means of proVasopressin, in particular copeptin or neurophysin II
SE532103C2 (en) 2006-12-12 2009-10-27 Knut Johansen Method for determining the health status of analytes in liquid samples
DE102007022367A1 (en) * 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Method for the determination of amino-terminal pro-ANP in overweight patients
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
JP5059943B2 (en) 2007-08-03 2012-10-31 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of procalcitonin (PCT) in risk stratification and in vitro methods for performing prognosis of patients with primary non-infectious diseases
EP2020603A1 (en) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Method for risk stratification in stable coronary artery disease
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
EP2031397A1 (en) * 2007-08-30 2009-03-04 F. Hoffmann-La Roche AG Surfactant proteins B and D in differentiating the causes of shortness of breath
US7955822B2 (en) 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
US8852893B2 (en) 2007-09-14 2014-10-07 Physicians Choice Laboratory Services, Llc Detection of nucleic acids and proteins
CA2717763A1 (en) * 2008-03-04 2009-09-11 John Bilello Diagnosing and monitoring depression disorders based on multiple biomarker panels
CA2718251A1 (en) * 2008-03-10 2009-09-17 Lineagen, Inc. Copd biomarker signatures
CA2718273A1 (en) * 2008-03-12 2009-09-17 Ridge Diagnostics, Inc. Inflammatory biomarkers for monitoring depression disorders
US7776522B2 (en) 2008-04-24 2010-08-17 Becton, Dickinson And Company Methods for diagnosing oncogenic human papillomavirus (HPV)
JP2011528115A (en) * 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー Multi-marker panel for diagnosis, monitoring and treatment selection of patients with heart failure
EP3336551B1 (en) 2008-08-11 2023-05-31 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
JP2011530705A (en) * 2008-08-13 2011-12-22 エフ．ホフマン−ラ ロシュ アーゲー D-dimer for pulmonary embolism, troponin, NT-proBNP
JP5219048B2 (en) * 2008-09-17 2013-06-26 独立行政法人農業・食品産業技術総合研究機構 Method for evaluating animal stress using anti-porcine interleukin-18 antibody
EP2166358A1 (en) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof
EP2356450B1 (en) * 2008-10-24 2019-02-06 B.R.A.H.M.S GmbH Prognosis and risk assessment in stroke patients by determining the level of marker peptides
JP5767973B2 (en) * 2008-11-18 2015-08-26 リッジ ダイアグノスティックス，インコーポレイテッド Metabolic syndrome biomarker and HPA axis biomarker for major depressive disorder
EP2405929B1 (en) 2009-03-11 2018-06-06 Promedior Inc. A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease
DK2405928T3 (en) 2009-03-11 2017-01-30 Promedior Inc Treatment and diagnosis procedure for hypersensitive diseases
MX357528B (en) 2009-05-11 2018-07-13 Berg Llc METHODS FOR THE TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC EXCHANGERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES OR ENVIRONMENTAL INFLUENCES.
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
DK2470910T3 (en) 2009-08-28 2017-04-03 Brahms Gmbh Procalcitonin for the prognosis of side effects
ES2687469T3 (en) 2009-09-14 2018-10-25 Banyan Biomarkers, Inc. Autoantibody markers for the diagnosis of head trauma
US10830773B2 (en) 2009-12-20 2020-11-10 Astute Medical, Inc. Methods for prognosis of future acute renal injury and acute renal failure
NZ601590A (en) * 2010-02-05 2014-10-31 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112012022509A2 (en) * 2010-03-08 2017-09-26 Brahms Gmbh Procalcitonin for the diagnosis of bacterial infections and antibiotic treatment guidance in patients with non-specific complaints.
JP5814337B2 (en) 2010-03-22 2015-11-17 ステミナ バイオマーカー ディスカバリー， インコーポレイテッド Prediction of human developmental toxicity of drugs using human stem cell-like cells and metabolomics
WO2011139914A1 (en) * 2010-04-29 2011-11-10 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
JP2013525820A (en) 2010-05-06 2013-06-20 シングレクス、インコーポレイテッド Methods for diagnosing, staging, predicting and identifying treatment responders for the risk of developing rheumatoid arthritis
CA2806816C (en) * 2010-07-28 2018-05-29 Abbott Gmbh & Co. Kg Method for detection of ischemic strokes
WO2012065095A2 (en) * 2010-11-11 2012-05-18 Medical University Of South Carolina Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling
EP2492691A1 (en) 2011-02-22 2012-08-29 Institut de Recerca Hospital Universitari Vall d'Hebron Method of predicting the evolution of a patient suffering of a neurovascular disease
WO2012123299A1 (en) 2011-03-11 2012-09-20 Roche Diagnostics Gmbh Asc as marker for chronic obstructive pulmonary disease (copd)
CN103608323B (en) 2011-04-04 2016-08-17 博格有限责任公司 The method for the treatment of central nerve neuroma
RU2469332C1 (en) * 2011-10-12 2012-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Differential diagnostic technique for bronchial asthma
EP3088900B1 (en) 2011-10-17 2020-08-12 Roche Diagniostics GmbH Troponin as marker for intermittent atrial fibrillation
ES2734494T3 (en) 2011-12-08 2019-12-10 Astute Medical Inc Methods and uses for the diagnosis of kidney injury and kidney failure
EP2597465A1 (en) * 2012-06-26 2013-05-29 Roche Diagniostics GmbH TnT and H-FABP for diagnosis of cardiac damage in infection
WO2014072500A1 (en) 2012-11-09 2014-05-15 Roche Diagnostics Gmbh Tnt based diagnosis of paroxysmal atrial fibrillation
US9295393B2 (en) 2012-11-09 2016-03-29 Elwha Llc Embolism deflector
CA2898581C (en) 2013-01-17 2022-07-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2014120731A1 (en) * 2013-02-01 2014-08-07 West Virginia University A biomarker algorithm for determining the time of stroke symptom onset and method
KR101494882B1 (en) 2013-02-21 2015-02-25 한국과학기술연구원 A composition for diagnosing acute myocardial infarction, a kit for diagnosing acute myocardial infarction comprising the composition, and a method for diagnosing acute myocardial infarction
CA2909094C (en) 2013-04-08 2023-06-27 Berg Llc Methods for the treatment of cancer using coenzyme q10 combination therapies
GB201309928D0 (en) * 2013-06-04 2013-07-17 Randox Lab Ltd Method
EP3757226A3 (en) 2013-07-17 2021-05-05 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
JP2016532115A (en) * 2013-08-30 2016-10-13 メタノミクス ゲーエムベーハー Means and methods for diagnosing heart failure in a subject
MX381399B (en) 2013-09-04 2025-03-12 Berg Llc COENZYME Q10 FORMULATIONS AND METHODS OF USE.
FR3010187A1 (en) * 2013-09-05 2015-03-06 Ct Hospitalier Universitaire Rouen USE OF UROTENSIN II AND / OR URP AS MARKERS FOR THE DIAGNOSIS OF POST HSA VASOSPASM
CN108627651A (en) 2013-09-20 2018-10-09 阿斯图特医药公司 The method and composition of the differentiation of diagnosis and prognosis and the abdominal pain cause of disease for appendicitis
US9784749B2 (en) * 2013-11-15 2017-10-10 Otago Innovation Limited Biomarker for cardiac disorders
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
EP3146077A4 (en) 2014-05-22 2018-05-02 The Scripps Research Institute Tissue molecular signatures of kidney transplant rejections
CN106661628A (en) 2014-05-22 2017-05-10 斯克利普斯研究院 Gene expression profiles associated with subclinical renal transplant rejection
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
WO2015179777A2 (en) 2014-05-22 2015-11-26 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3502271A3 (en) 2014-10-22 2019-08-14 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Blood biomarkers for appendicitis and diagnostics methods using biomarkers
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
US10690681B2 (en) 2015-03-06 2020-06-23 Washington University Methods to detect myocardial injury and uses thereof
WO2017067821A1 (en) * 2015-10-22 2017-04-27 Universite Pierre Et Marie Curie (Paris 6) A method for determining presence or risk of hemostasis disorder
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
KR101801092B1 (en) 2016-01-28 2017-11-28 순천향대학교 산학협력단 Composition for Idiopathic pulmonary fibrosis prognosis and method of providing the information for the same
CN109844526A (en) 2016-06-06 2019-06-04 机敏医药股份有限公司 Management of acute kidney injury using tissue inhibitors of insulin-like growth factor-binding protein 7 and metalloproteinase 2
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
CN108728525B (en) * 2017-04-19 2021-06-22 香港中文大学 Circulating microRNA biomarker for subarachnoid hemorrhage and application thereof
KR102356418B1 (en) * 2017-06-13 2022-02-08 에프. 호프만-라 로슈 아게 Fatty Acid Binding Protein 3 for Assessment of Atrial Fibrillation (AF)
US11685951B2 (en) 2017-07-18 2023-06-27 The Research Foundation For The State University Of New York Biomarkers for intracranial aneurysm
CN109975548B (en) * 2018-03-08 2020-08-07 中山大学 Application of IgG4 detection reagent in preparation of colorectal cancer diagnostic agent
EP4403923A3 (en) 2018-03-08 2024-11-27 Meso Scale Technologies, LLC Genetic marker and/or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury
WO2019189725A1 (en) * 2018-03-30 2019-10-03 国立研究開発法人国立精神・神経医療研究センター Neonatal hypoxic-ischemic encephalopathy severity determining method and prognosis predicting method
EP3553524A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Periodontitis diagnostic methods, uses and kits
EP3553518A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Periodontitis diagnostic methods, uses and kits
EP3553520A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Methods, uses and kits for monitoring or predicting response to periodontal disease treatment
EP3553526A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Methods, uses and kits for monitoring or predicting response to periodontal disease treatment
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3801596A4 (en) * 2018-05-29 2023-01-04 Evogen, Inc. BIOMARKERS AND METHODS OF ASSESSING AND METHODS OF TREATING EPILEPTIC SEIZURES VERSUS NON-EPILEPTIC SEIZURES/NON-EPILEPTIC SEIZURES/PSYCHOGENIC NON-EPILEPTIC SEIZURES
IT201800007264A1 (en) * 2018-07-17 2020-01-17 METHOD FOR IN VITRO DIAGNOSIS OF PROSTATE CARCINOMA USING URINARY BIOMARCATORS
JP7398226B2 (en) * 2019-09-03 2023-12-14 浜松ホトニクス株式会社 Methods for assessing the risk of developing colorectal cancer
US20230016954A1 (en) 2019-12-11 2023-01-19 Ichilov Tech Ltd. Non-invasive assay for differentiating between bacterial and viral infections
WO2021199792A1 (en) * 2020-04-02 2021-10-07 国立大学法人大阪大学 Formulation for preventing or treating pneumonia
CN114015759B (en) * 2020-07-24 2022-08-19 首都医科大学附属北京天坛医院 Biomarker for prognosis or recurrence early warning evaluation of acute ischemic stroke and application thereof
CN113252910B (en) * 2021-06-29 2022-05-17 中国人民解放军军事科学院军事医学研究院 Application of TIMP3 in the diagnosis of anxiety and depression
CN115287346A (en) * 2022-05-26 2022-11-04 中山大学深圳研究院 Acute myocardial infarction early detection marker and detection kit
CN116059328A (en) * 2022-09-14 2023-05-05 深圳先进技术研究院 Application of TIMP3 recombinant protein in the preparation of preparations for inhibiting hypertensive renal clear cell carcinoma
TW202444922A (en) 2023-03-31 2024-11-16 國立大學法人大阪大學 Biomarkers for predicting the prognosis of sepsis patients and their uses
CN120064628A (en) * 2025-02-28 2025-05-30 中国医学科学院阜外医院 Metabolic marker for evaluating operation prognosis of hypertrophic cardiomyopathy patient and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599668A (en) * 1994-09-22 1997-02-04 Abbott Laboratories Light scattering optical waveguide method for detecting specific binding events
US6214560B1 (en) * 1996-04-25 2001-04-10 Genicon Sciences Corporation Analyte assay using particulate labels
WO2003016910A1 (en) * 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20030153014A1 (en) * 1999-10-08 2003-08-14 Li Shen Compositions and methods for detecting protein modification and enzymatic activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604105B1 (en) * 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
AUPR005600A0 (en) * 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1666881B1 (en) * 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599668A (en) * 1994-09-22 1997-02-04 Abbott Laboratories Light scattering optical waveguide method for detecting specific binding events
US6214560B1 (en) * 1996-04-25 2001-04-10 Genicon Sciences Corporation Analyte assay using particulate labels
US20030153014A1 (en) * 1999-10-08 2003-08-14 Li Shen Compositions and methods for detecting protein modification and enzymatic activity
WO2003016910A1 (en) * 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1587955A4 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8029982B2 (en) 2004-01-20 2011-10-04 Alere San Diego, Inc. Biomarkers for sepsis
US9494598B2 (en) 2006-04-04 2016-11-15 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US8343728B2 (en) 2006-04-04 2013-01-01 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US9719999B2 (en) 2006-04-04 2017-08-01 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US8535895B2 (en) 2006-04-04 2013-09-17 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US9182405B2 (en) 2006-04-04 2015-11-10 Singulex, Inc. Highly sensitive system and method for analysis of troponin
US7842472B2 (en) 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US7985560B2 (en) 2006-11-14 2011-07-26 Alere San Diego, Inc. Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US8283128B2 (en) 2006-11-14 2012-10-09 Alere San Diego, Inc. Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US8524462B2 (en) 2006-11-14 2013-09-03 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
US8969018B2 (en) 2006-11-14 2015-03-03 Alere San Diego, Inc. Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US9395355B2 (en) 2007-12-28 2016-07-19 Roche Diagnostics Operations, Inc. Assessment of physiological conditions
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
US9541550B2 (en) 2011-05-09 2017-01-10 Sekisui Medical Co., Ltd. Method for immunologically measuring soluble LR11
US10732188B2 (en) 2011-12-01 2020-08-04 Roche Diagnostics Operations, Inc. NT-proANP and NT-proBNP for the diagnosis of stroke

Also Published As

Publication number Publication date
AU2003302340A1 (en) 2004-07-22
WO2004059293A2 (en) 2004-07-15
JP2006526140A (en) 2006-11-16
EP1587955A2 (en) 2005-10-26
AU2003302340B8 (en) 2008-09-11
AU2003302340B2 (en) 2008-08-21
CA2511501A1 (en) 2004-07-15
EP1587955A4 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
WO2004059293A3 (en) Markers for differential diagnosis and methods of use thereof
WO2002042775A3 (en) Clinically intelligent diagnostic devices and methods
WO2005027733A3 (en) Biological markers for diagnosing multiple sclerosis
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2003085095A3 (en) Novel expressed genes
WO2002089657A3 (en) Diagnostic markers of acute coronary syndromes and methods of use thereof
MXPA04000062A (en) Homocysteinylated transthyretin.
WO2004048598A3 (en) Molecular nephrotoxicology modeling
WO2003023573A3 (en) Patient classification
WO2004063753A3 (en) A serum marker for measuring liver fibrosis
WO2003047420A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2007030571A3 (en) Identification of targets and development of reagents for testing and molecular imaging of human disease
BR0317394A (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
WO2006024466A3 (en) Test device for the in vitro diagnosis of multi-analyte tests and the use thereof
BR0014150A (en) Diagnostics and therapeutics for osteoporosis
DE10292329D2 (en) Tools for the diagnosis, molecular definition and therapy development of chronic inflammatory joint diseases
WO2005072049A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2002092858A3 (en) Methods of screening for disease
WO2007011746A3 (en) Highly sensitive immunoassays and antibodies for detection of blood factor viii
EP1451552A4 (en) REAGENTS AND METHODS USEFUL IN THE DETECTION OF BREAST DISEASES
WO2003001182A3 (en) Homocysteinylated transthyretin
EP1572225A4 (en) THROMBOSPONDIN FRAGMENTS AND USES IN CLINICAL TRIALS ON CANCER AND PRODUCTION OF ANTIBODIES AND OTHER BINDING AGENTS
WO2002059617A3 (en) Standard diluent for multiplex assays
WO2004083241A3 (en) Btc-interacting proteins and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2511501

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 169348

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005510072

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 3018/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003302340

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003810896

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038A98399

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003810896

Country of ref document: EP